Discover the secrets of the psychedelic industry’s most successful leaders – a free weekly virtual series by Microdose
Episode 4 – June 3rd 2020
Diamond Therapeutics is developing FDA-approved, psilocybin-based therapeutics that deliver patient benefits without undesired perceptual side effects. Judy brings 25 years of experience in the life science sector, spanning from early to late stage investments. She is currently the Senior Director of Corporate Development at Toronto Innovation Acceleration Partners (TIAP), an early stage academic incubator, and is the CEO of Diamond Therapeutics.
Each week, we’ll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.